Handelsman David J, Goebel Catrin, Idan Amanda, Jimenez Mark, Trout Graham, Kazlauskas Rymantas
Andrology Department, Concord Hospital, ANZAC Research Institute, University of Sydney, Sydney NSW, Australia.
Clin Endocrinol (Oxf). 2009 Sep;71(3):417-28. doi: 10.1111/j.1365-2265.2008.03516.x. Epub 2008 Dec 18.
The administration of gonadotrophins is prohibited in sport but the effect in men of recently available recombinant hCG and LH on serum and urine concentrations of gonadotrophins and androgens has not been systematically evaluated in the antidoping context.
To determine the time-course of recombinant LH (rhLH) and hCG (rhCG) on blood and urine hormone profiles in men to develop effective tests to detect rhLH and rhCG doping.
Two randomized controlled studies with a 2 x 2 factorial design.
Academic research centre.
Healthy male volunteers aged 18-45 years.
In the rhLH study, men were randomized into (i) either of two single doses of rhLH (75 IU or 225 IU), and (ii) suppression of endogenous LH and testosterone by nandrolone or no suppression. In the rhCG study, men were randomized into (i) either of two single doses of rhCG (250 or 750 microg), and (ii) suppression of endogenous LH and testosterone by nandrolone decanoate (ND) or no suppression. ND suppression comprised a single dose of 200 mg ND 3 days prior to, and in the rhCG study an additional dose 1 day after gonadotrophin injection.
Serum and urine hCG, LH, T, T : LH ratio, urine epitestosterone (E) and urine T : E ratio.
Neither rhLH dose produced a significant increase in serum or urine LH or T or in the T : E or T : LH ratios regardless of ND-induced suppression of endogenous LH and T. Nor did an even higher dose (750 IU) in three healthy men with unsuppressed gonadal axis. These findings were confirmed with two different commercial LH immunoassays together with adjustment for any influence of urine sediment and dilution. Both rhCG doses produced a steep, dose-proportional increase in serum and urine hCG with increases in serum and urine T and suppression of serum and urine LH, regardless of hCG dose. Serum but not urine T was lowered by ND suppression. The T : LH ratio showed a progressive increase unrelated to rhCG dose or ND suppression, whereas both rhCG and ND suppression minimally increased T : E ratio.
Both rhCG doses produce a striking increase in serum hCG and T with suppression of serum LH but, at single doses up to 750 IU, rhLH has no influence on serum or urine LH or T. Effective rhLH doping, which relies on a sustained increases in endogenous T, would require much higher and more frequent daily rhLH doses. Use of LH immunoassays optimized for serum to detect rhLH doping by urine LH measurement requires more standardization and validation and, at present, is unreliable. The T : LH ratio is, however, a useful screening test for hCG doping although its utility requires further evaluation.
在体育赛事中禁止使用促性腺激素,但在反兴奋剂背景下,近期可用的重组人绒毛膜促性腺激素(hCG)和促黄体生成素(LH)对男性血清和尿液中促性腺激素及雄激素浓度的影响尚未得到系统评估。
确定重组LH(rhLH)和hCG(rhCG)对男性血液和尿液激素谱的时间进程,以开发有效的检测方法来检测rhLH和rhCG兴奋剂使用情况。
两项采用2×2析因设计的随机对照研究。
学术研究中心。
年龄在18 - 45岁的健康男性志愿者。
在rhLH研究中,男性被随机分为:(i)两种单剂量rhLH(75 IU或225 IU)中的一种,以及(ii)用诺龙抑制内源性LH和睾酮或不进行抑制。在rhCG研究中,男性被随机分为:(i)两种单剂量rhCG(250或750微克)中的一种,以及(ii)用癸酸诺龙(ND)抑制内源性LH和睾酮或不进行抑制。ND抑制包括在促性腺激素注射前3天给予200 mg ND单剂量,在rhCG研究中,促性腺激素注射后1天再额外给予一剂。
血清和尿液中的hCG、LH、睾酮(T)、T:LH比值、尿液表睾酮(E)以及尿液T:E比值。
无论ND诱导的内源性LH和T抑制情况如何,两种rhLH剂量均未使血清或尿液中的LH、T或T:E或T:LH比值出现显著升高。在三名性腺轴未受抑制的健康男性中给予更高剂量(750 IU)时也未出现这种情况。通过两种不同的商用LH免疫测定法以及对尿液沉淀和稀释的任何影响进行调整后,这些结果得到了证实。两种rhCG剂量均使血清和尿液中的hCG急剧、剂量成比例增加,同时血清和尿液中的T增加,血清和尿液中的LH受到抑制,且与hCG剂量无关。ND抑制使血清T降低,但尿液T未降低。T:LH比值呈渐进性升高,与rhCG剂量或ND抑制无关,而rhCG和ND抑制均使T:E比值略有增加。
两种rhCG剂量均使血清hCG和T显著增加,同时血清LH受到抑制,但单剂量高达750 IU的rhLH对血清或尿液中的LH或T没有影响。有效的rhLH兴奋剂使用依赖于内源性T的持续增加,这需要更高且更频繁的每日rhLH剂量。使用针对血清优化的LH免疫测定法通过测量尿液LH来检测rhLH兴奋剂使用需要更多的标准化和验证,目前并不可靠。然而,T:LH比值是检测hCG兴奋剂使用的有用筛查试验,尽管其效用还需要进一步评估。